株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ドラッグデリバリーデバイスの世界市場:市場分析、企業プロファイル、市場規模、市場シェア、成長、市場動向、市場予測

Global Drug Delivery Devices Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

発行 Data Bridge Market Research Private Limited 商品コード 536487
出版日 ページ情報 英文 350 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
ドラッグデリバリーデバイスの世界市場:市場分析、企業プロファイル、市場規模、市場シェア、成長、市場動向、市場予測 Global Drug Delivery Devices Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
出版日: 2017年12月01日 ページ情報: 英文 350 Pages
概要

当レポートでは、ドラッグデリバリーデバイスの世界市場を調査し、市場の概要、製品タイプ・エンドユーザー・流通チャネル・地域別の市場動向、市場規模の推移と予測、市場の将来展望、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 市場概要

第4章 エグゼクティブサマリー

第5章 重要考察

第6章 ドラッグデリバリーデバイス市場:製品タイプ

  • 市場概要
  • 経口投与型ドラッグデリバリー
    • 経口固形剤
    • 経口液剤
    • 半固形剤
  • 経肺ドラッグデリバリー
    • 定量噴霧式吸入器(MDI)
    • ドライパウダー式吸入器(DPI)
    • ネブライザー
  • 注入型ドラッグデリバリー
    • 従来型注射器
    • 自己注射器
    • 無針注射器
    • 自動注射器
    • ペン型注射器
    • ウェアラブル注射器
    • その他
  • 経鼻ドラッグデリバリー
    • 点鼻液
    • 点鼻スプレー
    • 点鼻粉剤
    • 点鼻ゲル
  • 局所ドラッグデリバリー
  • 埋込型ドラッグデリバリー
  • 口腔粘膜吸収型ドラッグデリバリー

第7章 ドラッグデリバリーデバイス市場:エンドユーザー別

  • 市場概要
  • 病院
  • 在宅ケア
  • 診療所
  • 地域医療
  • その他

第8章 ドラッグデリバリーデバイス市場:流通チャネル別

  • 市場概要
  • 病院内薬局
  • 薬局
  • 直接入札
  • オンライン薬局

第9章 ドラッグデリバリーデバイス市場:地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • トルコ
    • ベルギー
    • オランダ
    • スイス
    • その他
  • アジア太平洋
    • 日本
    • 中国
    • 韓国
    • インド
    • オーストラリア
    • シンガポール
    • タイ
    • マレーシア
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • ブラジル
    • その他
  • 中東・アフリカ
    • 南アフリカ
    • その他
  • 主要国の考察

第10章 競合情勢

  • 企業の市場シェア:全地域
  • 企業の市場シェア:米国
  • 企業の市場シェア:欧州
  • 企業の市場シェア:アジア太平洋

第11章 企業プロファイル

  • BAYER AG
  • JOHNSON & JOHNSON
  • NOVARTIS AG
  • PFIZER, INC.
  • F. HOFFMANN-LA ROCHE AG
  • GLAXOSMITHKLINE PLC
  • MERCK & CO.
  • ANTARES PHARMA, INC.
  • 3M
  • SANOFI
  • NEMERA

第12章 付録

第13章 免責事項

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Title:
Global Drug Delivery Devices Market
By Route of Administration (Oral, Injectable, Topical, Pulmonary, Nasal, Ocular, Implantable, Transmucosal), End-User (Hospitals, Clinics, Home Care Settings), Distribution Channel (Direct Tenders,Hospital Pharmacies), Geography (North America, Europe, Asia-Pacific, South America, Middle East Africa) - Trends and Forecast To 2024.

In this region, Global Drug Delivery Devices Market projected to USD 1,027.0 billion in 2016 growing at a CAGR of 8.1% during the forecast period of 2017 to 2024..

Based on geography, the global Drug Delivery Devices market is segmented into 5 geographical regions, such as,

  • North America,
  • South America,
  • Europe,
  • Asia-pacific,
  • Middle East and Africa .

Global Drug Delivery Devices market competition by top players including -

  • 3M Company,
  • Merck & Co., Inc.,
  • Pfizer Inc,
  • Johnson & Johnson,
  • Pfizer, Inc.,
  • Bayer AG,
  • F. Hoffmann-La Roche AG,
  • Sanofi,
  • Alkermes,
  • Abbott,
  • Novartis AG,
  • Valeant Pharmaceuticals International, Inc.,
  • Mylan Pharmaceuticals Inc.,
  • Antares Pharma,
  • Skye Pharma Plc.,
  • Nova Nordisk A/S,
  • Crossject,
  • Eli Lilly and Company,
  • Baxter International, Inc.,
  • Becton, Dickinson and Company,
  • Skyepharma AG

By product type, the global drug delivery devices market is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable and transmucosal.

Oral Drug Delivery is then segmented on the basis of form into solid oral drugs, liquid oral drugs and semi-solid oral drugs. The form of solid oral drugs is further sub segmented into tablets, capsules, powders, and pills.

Liquid oral drug is sub segmented into solutions and syrups.Semi-solid oral drug is sub segmented into gels, emulsions and elixirs.

Pulmonary Drug Delivery is segmented on the basis of formulations, devices and nebulizers.

On the basis of device the pulmonary drug delivery segment is further sub-segmented into in metered dose inhalers and dry powder inhaler.Nebulizers are sub segmented into Jet Nebulizers, Ultrasonic Nebulizers and Soft Mist Nebulizers.

The injectable drug delivery segment is further segmented on the basis of product type and formulations.

On the basis of type, the injectable drug delivery is segmented into self-injection devices, needle free injectors, auto-injectors, pen-injectors, wearable injectors.

On the basis of formulations the market is segmented into conventional drug delivery formulations, novel drug delivery formulations and long acting injection formulations.

The ophthalmic drug delivery is segmented on the basis of product type - ocular drug delivery devices and ocular drug delivery formulations.

The ocular drug delivery is further segmented by product type, drug coated contact lenses and ocular inserts.

The ocular drug delivery formulations is further segmented into liquid ocular drug delivery formulations and semi-solid ocular drug delivery formulations.

On the basis of type the liquid ocular drug delivery formulations is further sub segmented into eye drops and sprays.

On the basis of type the semi-solid ocular drug delivery formulations is sub segmented into gels and ointments.

The nasal drug delivery is segmented by type in nasal drops, nasal sprays, nasal powders and nasal gels.

The topical drug delivery is segmented on the basis of product type, transdermal drug delivery devices and topical drug delivery formulations.

On the basis of product type the transdermal drug delivery devices is further sub segmented in transdermal patches and transdermal gels.

On the basis of forms the topical drug delivery formulations are sub segmented into liquid topical drug delivery formulations, semi-solid topical drug delivery formulations, and solid topical drug delivery formulations.

The liquid topical drug delivery formulations are further sub segmented into solutions and suspensions.

The semi-solid topical drug delivery formulations are further sub segmented by type into creams, gels, ointments, pastes and lotions.

On the basis of type the solid topical drug delivery formulations is further sub segmented into suppositories and powders.

The implantable drug delivery is segmented by product type, active implantable drug delivery and passive implantable drug delivery.

On the basis of product type the transmucosal drug delivery is segmented in oral transmucosal drug delivery and other transmucosal drug delivery.

On the basis of type the oral transmucosal drug delivery is further sub segmented into buccal drug delivery and sublingual drug delivery.

The other transmucosal drug delivery is further sub segmented into rectal transmucosal drug delivery and vaginal transmucosal drug delivery.

On the basis of end users the market is segmented into hospitals, home healthcare, clinics, community healthcare and others.

On the basis of distribution channel the market is segmented in hospital pharmacies, pharmacy stores and direct tenders.

Table of Contents

1. INTRODUCTION

  • 1.1. OVERVIEW OF THE DRUG DELIVERY DEVICES MARKET
  • 1.2. CURRENCY AND PRICING
  • 1.3. LIMITATION
  • 1.4. MARKETS COVERED

2. RESEARCH METHODOLOGY

  • 2.1. MARKETS IN DRUG DELIVERY DEVICES MARKET
  • 2.2. GEOGRAPHICAL SCOPE
  • 2.3. YEARS CONSIDERED IN THE STUDY
  • 2.4. CURRENCY AND PRICING
  • 2.5. RESEARCH METHODOLOGY
    • 2.5.1. MARKET CRACKDOWN APPROACH
    • 2.5.2. COMPANY REVENUE AND MARKET SHARE ANALYSIS
    • 2.5.3. DATA TRIANGULATION
  • 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7. SECONDARY SOURCES
  • 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

4. EXECUTIVE SUMMARY

5. PREMIUM INSIGHTS

6. DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE

  • 6.1. OVERVIEW
  • 6.2. ORAL DRUG DELIVERY, BY FORM
    • 6.2.1. SOLID ORAL DRUGS, BY PRODUCT TYPE
      • 6.2.1.1. TABLETS
      • 6.2.1.2. CAPSULES
      • 6.2.1.3. POWDER
      • 6.2.1.4. PILLS
    • 6.2.2. LIQUID ORAL DRUGS, BY PRODUCT TYPE
      • 6.2.2.1. SOLUTIONS
      • 6.2.2.2. SYRUPS
    • 6.2.3. SEMI SOLID ORAL DRUGS, BY PRODUCT TYPE
      • 6.2.3.1. GELS
      • 6.2.3.2. EMULSIONS
      • 6.2.3.3. ELIXIRS
  • 6.3. PULMONARY DRUG DELIVERY, BY PRODUCT TYPE
    • 6.3.1. METERED DOSE INHALERS (MDI)
    • 6.3.2. DRY POWDER INHALERS (DPI)
    • 6.3.3. NEBULIZERS
      • 6.3.3.1. JET NEBULIZERS
      • 6.3.3.2. ULTRASONIC NEBULIZERS
      • 6.3.3.3. SOFT MIST NEBULIZERS
  • 6.4. INJECTABLE DRUG DELIVERY, BY PRODUCT TYPE
    • 6.4.1. INJECTABLE DRUG DELIVERY DEVICES, BY PRODUCT TYPE
      • 6.4.1.1. CONVENTIONALS INJECTABLES, BY MATERIAL
        • 6.4.1.1.1. GLASS
        • 6.4.1.1.2. PLASTIC
      • 6.4.2.2. CONVENTIONALS INJECTABLES, BY PRODUCT TYPE
        • 6.4.2.2.1. FILLABLE
        • 6.4.2.2.2. PRE-FILLED
      • 6.4.3.3. CONVENTIONALS INJECTABLES, BY USABILITY
        • 6.4.3.3.1. REUSABLE SYRIGES
        • 6.4.3.3.2. DISPOSABLE SYRINGES
      • 6.4.3.4. SELF INJECTION DEVICES
      • 6.4.3.5. NEEDLE FREE INJECTORS
      • 6.4.3.6. AUTOINJECTORS
      • 6.4.3.7. PEN INJECTORS
      • 6.4.3.8. WEARABLE INJCTORS
      • 6.4.3.9. OTHERS
    • 6.4.2. INJECTABLE DRUG DELIVERY FORMULATIONS, BY PRODUCT TYPE
      • 6.4.2.1. CONVENTIONAL DRUG DELIVERY FORMULATIONS
      • 6.4.2.2. NOVEL DRUG DELIVERY FORMULATIONS
      • 6.4.2.3. LONG ACTING INJECTION FORMULATIONS
  • 6.5. OPTHALMIC DRUG DELIVERY, BY PRODUCT TYPE
    • 6.5.1. OCCULAR DRUG DELIVERY DEVICES, BY PRODUCT TYPE
      • 6.5.1.1. DRUG COATED CONTACT LENSES
      • 6.5.1.2. OCCULAR INSERTS
    • 6.5.2. OCCULAR DRUG DELIVERY FORMULATIONS, BY FORM
      • 6.5.2.1. LIQUID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.5.2.1.1. EYE DROPS
        • 6.5.2.1.2. SPRAYS
      • 6.5.2.2. SEMI-SOLID OCCULAR DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.5.2.2.1. GELS
        • 6.5.2.2.2. OINTMENTS
  • 6.6. NASAL DRUG DELIVERY, BY PRODUCT TYPE
    • 6.6.1. NASAL DROPS
    • 6.6.2. NASAL SPRAYS
    • 6.6.3. NASAL POWDERS
    • 6.6.4. NASAL GELS
  • 6.7. TOPICAL DRUG DELIVERY, BY PRODUCT TYPE
    • 6.7.1. TRANSDERMAL DRUG DELIVERY DEVICES, BY PRODUCT TYPE
      • 6.7.1.1. TRANSDERMAL PATCHES
      • 6.7.1.2. TRANSDERMAL GELS
    • 6.7.2. TOPICAL DRUG DELIVERY FORMULATIONS, BY FORM
      • 6.7.2.1. LIQUID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.7.2.1.1. SOLUTIONS
        • 6.7.2.1.2. SUSPENSIONS
      • 6.7.2.2. SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.7.2.2.1. GELS
        • 6.7.2.2.2. CREAMS
        • 6.7.2.2.3. OINTMENTS
        • 6.7.2.2.4. PASTES
        • 6.7.2.2.5. LOTIONS
      • 6.7.2.3. SOLID TOPICAL DRUG DELIVERY FORMULATIONS, BY TYPE
        • 6.7.2.3.1. SUPPOSITORIES
        • 6.7.2.3.2. POWDERS
  • 6.8. IMPLANTABLE DRUG DELIVERY, BY PRODUCT TYPE
    • 6.8.1. ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES
    • 6.8.2. PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES
  • 6.9. TRANSMUCOSAL DRUG DELIVERY, BY PRODUCT TYPE
    • 6.9.1. ORAL TRANSMUCOSAL DRUG DELIVERY, BY TYPE
      • 6.9.1.1. BUCCAL DRUG DELIVERY
      • 6.9.1.2. SUBLINGUAL DRUG DELIVERY
    • 6.9.2. OTHER TRANSMUCOSAL DRUG DELIVERY, BY TYPE
      • 6.9.2.1. RECTAL TRANSMUCOSAL DRUG DELIVERY
      • 6.9.2.2. TRANSMUCOSAL TRANSMUCOSAL DRUG DELIVERY

7. DRUG DELIVERY DEVICES MARKET, BY END-USER

  • 7.1. OVERVIEW
  • 7.2. HOSPITALS
  • 7.3. HOME HEALTHCARE
  • 7.4. CLINICS
  • 7.5. COMMUNITY HEALTHCARE
  • 7.6. OTHERS

8. DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL

  • 8.1. OVERVIEW
  • 8.2. HOSPITAL PHARMACIES
  • 8.3. PHARMACY STORES
  • 8.4. DIRECT TENDERS
  • 8.5. ONLINE PHARMACY

9. DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY

  • 9.1. COUNTRYWISE DRUG DELIVERY DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
    • 9.1.1. NORTH AMERICA
      • 9.1.1.1. U.S.
      • 9.1.1.2. CANADA
      • 9.1.1.3. MEXICO
    • 9.1.2. EUROPE
      • 9.1.2.1. GERMANY
      • 9.1.2.2. FRANCE
      • 9.1.2.3. U.K.
      • 9.1.2.4. ITALY
      • 9.1.2.5. SPAIN
      • 9.1.2.6. RUSSIA
      • 9.1.2.7. TURKEY
      • 9.1.2.8. BELGIUM
      • 9.1.2.9. NETHERLANDS
      • 9.1.2.10. SWITZERLAND
      • 9.1.2.11. REST OF EUROPE
    • 9.1.3. ASIA-PACIFIC (APAC)
      • 9.1.3.1. JAPAN
      • 9.1.3.2. CHINA
      • 9.1.3.3. SOUTH KOREA
      • 9.1.3.4. INDIA
      • 9.1.3.5. AUSTRALIA
      • 9.1.3.6. SINGAPORE
      • 9.1.3.7. THAILAND
      • 9.1.3.8. MALAYSIA
      • 9.1.3.9. INDONESIA
      • 9.1.3.10. PHILIPPINES
      • 9.1.3.11. REST OF APAC
    • 9.1.4. LATIN AMERICA
      • 9.1.4.1. BRAZIL
      • 9.1.4.2. REST OF LATIN AMERICA
    • 9.1.5. MIDDLE EAST AND AFRICA
      • 9.1.5.1. SOUTH AFRICA
      • 9.1.5.2. REST OF MIDDLE EAST AND AFRICA
  • 9.2. KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES

10. DRUG DELIVERY DEVICES MARKET: COMPETITIVE LANDSCAPE

  • 10.1. GLOBAL DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
  • 10.2. U.S. DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
  • 10.3. EUROPE DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS
  • 10.4. APAC DRUG DELIVERY DEVICES MARKET: COMPANY SHARE ANALYSIS

11. DRUG DELIVERY DEVICES MARKET, COMPANY PROFILES

  • 11.1. BAYER AG
    • 11.1.1. COMPANY OVERVIEW
    • 11.1.2. REVENUE ANALYSIS
    • 11.1.3. PRODUCT PORTFOLIO
    • 11.1.4. RECENT DEVELOPEMENTS
    • 11.1.5. DATA BRIDGE ANALYSIS
  • 11.2. JOHNSON & JOHNSON
    • 11.2.1. COMPANY OVERVIEW
    • 11.2.2. REVENUE ANALYSIS
    • 11.2.3. PRODUCT PORTFOLIO
    • 11.2.4. RECENT DEVELOPEMENTS
    • 11.2.5. DATA BRIDGE ANALYSIS
  • 11.3. NOVARTIS AG
    • 11.3.1. COMPANY OVERVIEW
    • 11.3.2. REVENUE ANALYSIS
    • 11.3.3. PRODUCT PORTFOLIO
    • 11.3.4. RECENT DEVELOPEMENTS
    • 11.3.5. DATA BRIDGE ANALYSIS
  • 11.4. PFIZER, INC.
    • 11.4.1. COMPANY OVERVIEW
    • 11.4.2. REVENUE ANALYSIS
    • 11.4.3. PRODUCT PORTFOLIO
    • 11.4.4. RECENT DEVELOPEMENTS
    • 11.4.5. DATA BRIDGE ANALYSIS
  • 11.5. F. HOFFMANN-LA ROCHE AG
    • 11.5.1. COMPANY OVERVIEW
    • 11.5.2. REVENUE ANALYSIS
    • 11.5.3. PRODUCT PORTFOLIO
    • 11.5.4. RECENT DEVELOPEMENTS
    • 11.5.5. DATA BRIDGE ANALYSIS
  • 11.6. GLAXOSMITHKLINE PLC
    • 11.6.1. COMPANY OVERVIEW
    • 11.6.2. REVENUE ANALYSIS
    • 11.6.3. PRODUCT PORTFOLIO
    • 11.6.4. RECENT DEVELOPEMENTS
    • 11.6.5. DATA BRIDGE ANALYSIS
  • 11.7. MERCK & CO.
    • 11.7.1. COMPANY OVERVIEW
    • 11.7.2. REVENUE ANALYSIS
    • 11.7.3. PRODUCT PORTFOLIO
    • 11.7.4. RECENT DEVELOPEMENTS
    • 11.7.5. DATA BRIDGE ANALYSIS
  • 11.8. ANTARES PHARMA, INC.
    • 11.8.1. COMPANY OVERVIEW
    • 11.8.2. REVENUE ANALYSIS
    • 11.8.3. PRODUCT PORTFOLIO
    • 11.8.4. RECENT DEVELOPEMENTS
    • 11.8.5. DATA BRIDGE ANALYSIS
  • 11.9. 3M
    • 11.9.1. COMPANY OVERVIEW
    • 11.9.2. REVENUE ANALYSIS
    • 11.9.3. PRODUCT PORTFOLIO
    • 11.9.4. RECENT DEVELOPEMENTS
    • 11.9.5. DATA BRIDGE ANALYSIS
  • 11.10. SANOFI
    • 11.10.1. COMPANY OVERVIEW
    • 11.10.2. REVENUE ANALYSIS
    • 11.10.3. PRODUCT PORTFOLIO
    • 11.10.4. RECENT DEVELOPEMENTS
    • 11.10.5. DATA BRIDGE ANALYSIS
  • 11.11. NEMERA
    • 11.11.1. COMPANY OVERVIEW
    • 11.11.2. REVENUE ANALYSIS
    • 11.11.3. PRODUCT PORTFOLIO
    • 11.11.4. RECENT DEVELOPEMENTS
    • 11.11.5. DATA BRIDGE ANALYSIS

12. APPENDIX

13. DISCLAIMER

Back to Top